All topicsSTATE OF AI REPORT.

Which AI-assisted medicines have reached Phase 3?

By Nathan Benaich (Air Street Capital)

Generate:Biomedicines’ GB-0895 for severe asthma and Insilico’s rentosertib for idiopathic pulmonary fibrosis have recruiting Phase 3 trials in ClinicalTrials.gov. AI-assisted drug discovery is reaching late-stage clinical development. Human trials will determine whether these medicines are safe and effective.

Source: ClinicalTrials.gov: GB-0895, NCT07276724 · ClinicalTrials.gov: rentosertib, NCT07687459.

Evidence you can use

Two recruiting Phase 3 programs

Registry checked 2026-10-07

Two recruiting Phase 3 programs
MedicineConditionRegistry status
GB-0895SourceSevere asthmaPhase 3 · Recruiting
Rentosertib (INS018_055)SourceIdiopathic pulmonary fibrosisPhase 3 · Recruiting

Selected programs from the report, checked against the ClinicalTrials.gov API. GB-0895’s record was updated on 2026-10-07 and rentosertib’s on 2026-09-17. Trial phase and recruitment status do not establish efficacy, regulatory approval, or how much of development was performed using AI.

Sources: ClinicalTrials.gov: GB-0895, NCT07276724 · ClinicalTrials.gov: rentosertib, NCT07687459.

Data & methodology →Download CSVJSON

New businesses are forming around drug discovery

The good news for entrepreneurs in biotech is that new business models are emerging around drug discovery that aren’t about owning drugs. For example, Tempus licenses oncology data for foundation-model development with AstraZeneca and Pathos, while GSK's five-year Noetik agreement includes annual fees for access to virtual-cell models for cancer research.

Frequently asked questions

Answers drawn from the report and the sources below.

Sources and dates

2026 report snapshot. Preview revised 2026-10-07. Individual data periods and source checks are listed below. This is not a claim that every source was updated on that date.

  1. ClinicalTrials.gov: GB-0895, NCT07276724Registry updated 2026-10-07. Registry API checked 2026-10-07.
  2. ClinicalTrials.gov: rentosertib, NCT07687459Registry updated 2026-09-17. Registry API checked 2026-10-07.
  3. Noetik: GSK licenses OCTO2026. Retained from the launch essay.
  4. State of AI Report 2026, slide 67: OpenAI graduates from Erdős problems to a $1M Millennium Prize problem2026 report snapshot. Read against the report PDF on 2026-10-07. Study-specific limits retained.
  5. State of AI Report 2026, slide 70: Verification cuts fabricated results, while human scientific oversight remains essential2026 report snapshot. Read against the report PDF on 2026-10-07. Study-specific limits retained.
  6. State of AI Report 2026, slide 71: Nearly half of frontier models’ “done” claims in lab-handling tasks were incomplete2026 report snapshot. Read against the report PDF on 2026-10-07. Study-specific limits retained.
  7. State of AI Report 2026, slide 76: Using a binding predictor more than doubles the yield of designed nanobodies2026 report snapshot. Read against the report PDF on 2026-10-07. Study-specific limits retained.
  8. State of AI Report 2026, slide 77: Chai's designed antibodies pass laboratory tests beyond binding2026 report snapshot. Read against the report PDF on 2026-10-07. Study-specific limits retained.
  9. State of AI Report 20262026 report snapshot. Report PDF. See individual slide references for the expanded analysis.
  10. oncology data - investors.tempus.comOriginal source link retained from the launch essay.

Cite this page

Benaich, Nathan. “Which AI-assisted medicines have reached Phase 3?.” State of AI Report 2026. Published 2026-10-08.